DOI: 10.3390/ph19101655 ISSN: 1424-8247

Detachable Modular Blood–Brain Barrier-on-a-Chip with a Concentration Gradient Generator for Stepwise Inflammation Modeling and Drug Evaluation

Zezhi Li, Haizhu Meng, Xinmeng Liao, Shuqi Wang, Dan Hu, Lijuan Chen, Yuanhang Chang, Junwei Zhao, Xiang Li, Jianping Xie

Background/Objectives: The blood–brain barrier (BBB) is compromised in many neurological disorders, yet in vitro models rarely reproduce graded inflammatory stimulation of brain endothelial cells in vivo. This study developed a detachable, modular BBB-on-a-chip for stepwise inflammation modeling with multi-marker readout, and compared the anti-inflammatory efficacy of quercetin (QUER) and kaempferol (KAE). Methods: The chip combines a Christmas-tree concentration gradient generator with a four-channel culture module, fabricated separately and assembled on demand for stepwise seeding, exposure, dosing, and sampling. hCMEC/D3 cells were exposed to a TNF-α gradient (0–30 ng/mL); extracellular ATP, ROS, NO, cytokines, ZO-1, and ICAM-1 were monitored over 48 h. Transcriptomics and network pharmacology were integrated with molecular docking and 100 ns molecular dynamics simulations; QUER and KAE were administered gradient-wise (0–20 μM), with dexamethasone as a control. Results: The TNF-α gradient induced time- and concentration-dependent injury, with ATP and IL-8 responding at 8 h, ROS and NO at 12 h, and IL-1β, IL-6, and tight-junction impairment later, yielding spatiotemporally resolved readouts across four parallel channels. Ten hub inflammatory genes, including ICAM1, were identified, and network pharmacology nominated QUER. QUER was predicted to bind ICAM-1 more strongly than KAE, its structural analog differing by one B-ring hydroxyl group; gradient administration confirmed QUER suppressed ICAM-1 expression and inflammatory mediator release at lower concentrations. Conclusions: The detachable modular design makes multi-step inflammation modeling and gradient-based anti-inflammatory evaluation convenient on a single chip; QUER’s consistent advantage over KAE across binding calculations and functional assays supports a structure-activity relationship consistent with ICAM-1 engagement.

More from our Archive